We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$315M 6.94%
571,039
-7,835
-1% -$4.55M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$310M 6.84%
7,853,198
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$229M 5.04%
1,820,000
– –
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$35.7B
$221M 4.86%
676,367
-91,780
-12% -$25.4M
ABT icon
5
Abbott
ABT
$175B
$213M 4.69%
1,564,022
+7,893
+0.5% +$1.04M
SYK icon
6
Stryker
SYK
$123B
$212M 4.67%
535,089
-31,508
-6% -$11.8M
ISRG icon
7
Intuitive Surgical
ISRG
$122B
$206M 4.54%
378,728
-47,018
-11% -$24.6M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$197M 4.33%
441,610
+28,539
+7% +$13.2M
BSX icon
9
Boston Scientific
BSX
$65.4B
$190M 4.18%
1,765,194
-185,826
-10% -$18.8M
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$168M 3.71%
4,579,300
+205,000
+5% +$7.88M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$119M 2.63%
3,590,150
+75,000
+2% +$2.27M
INCY icon
12
Incyte
INCY
$23.4B
$107M 2.36%
1,570,333
-521,447
-25% -$33M
AKRO
13
DELISTED
Akero Therapeutics
AKRO
$106M 2.33%
1,985,272
+734,606
+59% +$33.4M
SRRK icon
14
Scholar Rock
SRRK
$6.33B
$104M 2.3%
2,947,295
+440,405
+18% +$13.8M
MDT icon
15
Medtronic
MDT
$106B
$80.3M 1.77%
921,043
-17,312
-2% -$1.47M
IMCR icon
16
Immunocore
IMCR
$1.78B
$76.6M 1.69%
2,441,830
+1,220,036
+100% +$37.9M
DXCM icon
17
DexCom
DXCM
$29.6B
$75.1M 1.66%
860,828
-203,280
-19% -$15.9M
EW icon
18
Edwards Lifesciences
EW
$49.4B
$69.5M 1.53%
889,077
-82,892
-9% -$6.18M
PODD icon
19
Insulet
PODD
$11.4B
$68.8M 1.52%
219,013
-52,273
-19% -$15.1M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$67.3M 1.48%
3,307,569
+235,954
+8% +$4.59M
BDX icon
21
Becton Dickinson
BDX
$43.6B
$54.6M 1.2%
316,732
-27,579
-8% -$5.05M
BEAM icon
22
Beam Therapeutics
BEAM
$2.83B
$49.1M 1.08%
2,889,288
+493,358
+21% +$8.59M
TMO icon
23
Thermo Fisher Scientific
TMO
$198B
$46M 1.01%
113,544
+49,312
+77% +$20.6M
PEN icon
24
Penumbra
PEN
$12.5B
$44.7M 0.98%
174,050
-30,467
-15% -$8.29M
UNH icon
25
UnitedHealth
UNH
$387B
$44.4M 0.98%
142,296
-22,446
-14% -$8.58M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.